Human Fibroblast Growth Factor Market Report 2026

The human fibroblast growth factor market size has grown rapidly in recent years. It will grow from $1.1 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growth in regenerative medicine research, increasing demand for human tissue derived proteins, rising investment in biotech R&D, expansion of hospital and research institute networks, adoption of hfgf in diagnostic applications.

The human fibroblast growth factor market size is expected to see rapid growth in the next few years. It will grow to $1.83 billion by 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing adoption of recombinant hfgf products, growth in tissue engineering and cell therapy markets, rising use in high-throughput drug screening, advancements in protein stabilization technologies, expansion of direct sales and e-commerce channels. Major trends in the forecast period include increasing development of recombinant hfgf variants, rising use of hfgf in tissue engineering applications, expansion of high-purity and lyophilized formulations, growing adoption of hfgf in drug screening platforms, integration of hfgf solutions with cell proliferation research.

The rising incidence of chronic diseases is expected to drive the growth of the human fibroblast growth factor market in the coming years. Chronic diseases are long-lasting health conditions, typically persisting for three months or more, often progressing slowly and rarely cured completely, although symptoms can be managed, often requiring ongoing medical attention or long-term medication. The increase in chronic diseases is linked to lifestyle changes and environmental factors associated with modern life, accumulating over time to cause long-term health issues. Human fibroblast growth factor aids in preventing chronic diseases by enabling tissue repair, new blood vessel formation, and reducing chronic inflammation, thereby lowering the risk and progression of long-term health conditions. For instance, in 2025, The Northern Arizona Medical Group, a US-based healthcare provider, projected that nearly three-quarters of the global population will live with at least one chronic illness, with prevalence continuing to rise. In the United States in 2023, approximately 76.4% of adults reported having at least one chronic condition, and 51.4% had two or more. Consequently, the increasing incidence of chronic diseases is driving the growth of the human fibroblast growth factor market.

Leading companies operating in the human fibroblast growth factor market are advancing synthetic growth factor engineering, enabling the creation of peptide or protein mimetics that replicate the biological activity of native FGFs while offering greater stability, reduced degradation, improved receptor specificity, and lower production costs. Synthetic growth factor engineering involves designing artificially created or modified molecules to mimic or enhance natural growth factor activity while improving stability, specificity, and manufacturability. For example, in October 2024, PeptiGrowth Inc, a Japan-based biotechnology company, launched a novel synthetic peptide growth factor that mimics natural growth factor activity while improving stability and efficiency. The peptides provide prolonged activity in cell culture systems, reducing the need for frequent media replacement and ensuring consistent experimental results.

In August 2023, Danaher Corporation, a U.S.-based global science and technology company specializing in life sciences, diagnostics, and biotechnology solutions, acquired Abcam plc for approximately $5.7 billion. Through this acquisition, Danaher gained access to Abcam’s extensive portfolio of recombinant proteins, antibodies, and life science research reagents, including human fibroblast growth factors widely used in cell culture, stem cell research, and regenerative medicine applications. Abcam plc is a UK-based biotechnology company specializing in the development and supply of high-quality antibodies, recombinant proteins, and assays for research, diagnostic, and drug discovery applications.

Major companies operating in the human fibroblast growth factor market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Bio‑Techne Corporation, STEMCELL Technologies Inc., GenScript Biotech Corporation, Promega Corporation, Sino Biological Inc., Cell Signaling Technology Inc, ACROBiosystems Co. Ltd., RayBiotech Inc., Proteintech Group Inc., PromoCell GmbH, Creative Biolabs Co. Ltd., BPS Bioscience Inc., MedChemExpress LLC, ProSpec‑Tany Technogene Ltd., Novoprotein Scientific Inc., Elabscience Biotechnology Inc., Enzo Life Sciences Inc.

North America was the largest region in the human fibroblast growth factor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human fibroblast growth factor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the human fibroblast growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human fibroblast growth factor (hFGF) market includes of revenues earned by entities by providing services such as wound healing and tissue repair, angiogenesis, cosmetic and dermatology applications, drug development services, metabolic and systemic health support, and laboratory and biotechnology applications. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The human fibroblast growth factor (hFGF) market consists of sales of wound healing gels and creams, ophthalmic preparations, bone and cartilage repair products, anti-aging serums and creams, cell culture supplements, and drug screening kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.